The Impact of Recombinant Human Erythropoietin Administration in Critically ill COVID-19 Patients: A Multicenter Cohort Study

Al Sulaiman, Khalid, Aljuhani, Ohoud, Korayem, Ghazwa B., Altebainawi, Ali F., Vishwakarma, Ramesh, AlFaifi, Mashael, Alsohimi, Samiah, Alrayes, Aljoharah, Albishi, Sara, Alqahtani, Reem, Alalawi, Mai, Al Sulaihim, Ibrahim, Alanazi, Thamer A., Alqahtani, Rahaf A., Almagthali, Alaa, Jomah, Shahamah, Alshlowi, Areej, Alshammari, Tahani R., Alzahrani, Shahad S. and Abdulqader, Marwa I. (2023) The Impact of Recombinant Human Erythropoietin Administration in Critically ill COVID-19 Patients: A Multicenter Cohort Study. Clinical and Applied Thrombosis/Hemostasis, 29. pp. 1-10. ISSN 1076-0296

Microsoft Word (rba11-al-sulaiman-et-al-2023-th) - Published Version Available under License Creative Commons Attribution Non-commercial. Download (457kB)

Abstract

The use of erythropoietin-stimulating agents (ESAs) as adjunctive therapy in critically ill patients with COVID-19 may have a potential benefit. This study aims to evaluate the effect of ESAs on the clinical outcomes of critically ill COVID-19 patients. A multicenter, retrospective cohort study was conducted from 01-03-2020 to 31-07-2021. We included adult patients who were ≥ 18 years old with a confirmed diagnosis of COVID-19 infection and admitted to intensive care units (ICUs). Patients were categorized depending on ESAs administration during their ICU stay. The primary endpoint was the length of stay; other endpoints were considered secondary. After propensity score matching (1:3), the overall included patients were 120. Among those, 30 patients received ESAs. A longer duration of ICU and hospital stay was observed in the ESA group (beta coefficient: 0.64; 95% CI: 0.31-0.97; P = <.01, beta coefficient: 0.41; 95% CI: 0.12-0.69; P = <.01, respectively). In addition, the ESA group's ventilator-free days (VFDs) were significantly shorter than the control group. Moreover, patients who received ESAs have higher odds of liver injury and infections during ICU stay than the control group. The use of ESAs in COVID-19 critically ill patients was associated with longer hospital and ICU stays, with no survival benefits but linked with lower VFDs.

Item Type:	Article
Additional Information:	The datasets used and/or analyzed during the current study are available from corresponding author on reasonable request. We would like to thank the investigators who participated in this project from the Saudi critical care pharmacy research (SCAPE) platform.
Uncontrolled Keywords:	covid-19,critically ill,erythropoietin-stimulating agents,esa,length of stay,mortality,ventilator-free days (vfds),hematology ,/dk/atira/pure/subjectarea/asjc/2700/2720
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Centres > Public Health Faculty of Medicine and Health Sciences > Research Centres > Population Health (former - to 2025)
Related URLs:	http://www.scopus.com/inward/record.url?...
Depositing User:	LivePure Connector
Date Deposited:	14 Apr 2026 13:34
Last Modified:	14 Apr 2026 13:34
URI:	https://ueaeprints.uea.ac.uk/id/eprint/102777
DOI:	10.1177/10760296231218216

Downloads

Actions (login required)

View Item